Infección tuberculosa latente en población indigente. Comparación de dos pautas terapéuticas

Sánchez-Arcilla, Ignacio; Vílchez, José María; García de la Torre, Manuel; Fernández, Xiomara; Noguerado, Arturo.
Med. clín (Ed. impr.) ; 122(2): 57-59, ene. 2004.
Artigo em Es | IBECS (Espanha) | ID: ibc-29055

Documentos relacionados

  1. Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study.
  2. Optimising pyrazinamide for the treatment of tuberculosis.
  3. Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis.
  4. Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen.
  5. Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data.
  6. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
  7. Variation in Treatment of Pediatric Tuberculosis Infection in Different Provider Settings.
  8. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
  9. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
  10. In TB, an 8-wk, 5-drug regimen was noninferior to a standard 24-wk, 4-drug regimen for clinical outcomes at 96 wk.